Applied DNA Sciences, Inc. Seeks Expansion of Linea™ Mpox Virus 1.0 Assay
Stony Brook, NY / ACCESSWIRE / August 19, 2024
Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA) has announced its intention to seek an expansion of the approved intended use of its Linea™ Mpox Virus 1.0 Assay to include the detection of mpox Clade I. This specific strain has been identified by the World Health Organization (WHO) as a public health emergency of international concern. The company’s internal data has shown that the Assay is capable of detecting the genetic sequence of mpox Clade I, prompting Applied DNA to conduct validation studies for documentation submission to the New York State Department of Health (NYSDOH).
The Linea™ Mpox Virus 1.0 Assay, originally designed for a different purpose, has shown promise in its ability to detect the mpox Clade I virus. This expansion could potentially have far-reaching implications for public health and safety, as early detection and accurate identification are critical in containing and controlling the spread of infectious diseases.
How will this affect me?
As a member of the public, having access to a reliable diagnostic tool like the Linea™ Mpox Virus 1.0 Assay could lead to quicker identification and treatment of infectious diseases. This could ultimately improve health outcomes and reduce the risk of widespread outbreaks in communities.
How will this affect the world?
The global impact of Applied DNA Sciences, Inc.’s expansion of the Linea™ Mpox Virus 1.0 Assay could be significant. By enhancing our ability to detect and respond to emerging infectious diseases, we may be better equipped to prevent pandemics and protect vulnerable populations around the world. This advancement in diagnostic technology has the potential to save lives and improve public health on a global scale.
Conclusion
Applied DNA Sciences, Inc.’s decision to seek an expansion of the Linea™ Mpox Virus 1.0 Assay is a significant step towards improving our ability to detect and respond to infectious diseases, particularly in light of the WHO’s recent declaration of a public health emergency. This development has the potential to benefit individuals and communities by enabling faster and more accurate diagnosis, ultimately contributing to a healthier and safer world.
